Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain

Journal of Nuclear Medicine

Volumn 41, Issue 6, 2000, Pages 1021-1024

  Papatheofanis, Frank J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

89Sr chloride; Metastasis; Palliation; Prostate cancer

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; STRONTIUM 89; STRONTIUM CHLORIDE;

AGED; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER PALLIATIVE THERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; BONE NEOPLASMS; E-SELECTIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STRONTIUM; STRONTIUM RADIOISOTOPES;

EID: 0034116841     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Ben-Josef E, Porter AT. Radioisotopes in the treatment of bone metastases. Ann Med. 1997;29:31-35.
2. Janjan NA. Radiation for bone metastases. Cancer. 1997;80:1628-1645.
3. Papatheofanis FJ, Windisch PA, Matuszewski KA. Systemic radionuclide palliative therapy for metastatic carcinoma with strontium 89. J Pharm Prac. 1997;10:352-350.
4. Krishnamurthy GT, Swailem FM, Srivastava SC, et al. Tin-117m (4+)DTPA: pharmacokinetics and imaging characteristics in patients with metastatic bone pain. J Nucl Med. 1997;38:230-237.
5. Srivastava SC, Atkins HL, Krishnamurthy GT, et al. Treatment of metastatic bone pain with Tin-117m stannic diethylenetriaminepentaacetic acid: phase I/II clinical study. Clin Cancer Res. 1998;4:61-64.
6. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol. 1994;31:33-40.
7. Tu SM, Delpassand ES, Jones D, Amato RJ, Ellerhorst J, Logothetis CJ. Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urol Oncol. 1996;2:191-197.
8. Gao X, Porter AT, Grignon DJ, Pontes JE, Honn KV. Diagnostic and prognostic markers for human prostate cancer. Prostate. 1997;31:264-281.
9. Lynch DF, Hassen W, Clements MA, Schellhammer PF, Wright GL Jr. Serum levels of endothelial and neural cell adhesion molecules in prostate cancer. Prostate. 1997;32:214-220.
10. Bird MI, Foster MR, Priest R, Malhotra R. Selectins: physiological and pathophysiological roles. Biochem Soc Trans. 1997;25;1199-1206.
11. Kannagi R. Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconj J. 1997;14:577-584.
12. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1986;61:195-202.
13. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1:277-299.
14. Wu JT. Assay for prostate specific antigen (PSA): problems and possible solutions. J Clin Lab Anal. 1994;8:51-62.
15. Ben-Josef E, Lucas RD, Vasan S, Porter AT. Selective accumulation of strontium-89 in metastatic deposits in bone: radio-histological correlation. Nucl Med Commun. 1995;16:457-463.
16. Daneker GW, Lund SA, Caughman SW, Staley CA, Wood WC. Anti-metastatic prostacyclins inhibit the adhesion of colon carcinoma to endothelial cells by blocking E-selectin expression. Clin Exp Metastases. 1996;14:230-238.
17. Porter AT, McEwan AJB, Powe JL, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805-813.